Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 9/20 | 0.54 |
| ▸ | NPC1 | O15118 | 8/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | GFER | P55789 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | METAP1 | P53582 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29919656 | 1.00 | RAB9A (0.54) | RAB9ANPC1KDM4EHTTATM | |
| SCHEMBL27967000 | 0.84 | RAB9A (0.49) | RAB9ANPC1KDM4EATML3MBTL1 | |
| SCHEMBL15266282 | 0.84 | METAP1 (0.56) | RAB9AKDM4EGFERPOLBMETAP1 | |
| SCHEMBL19522245 | 0.83 | RAB9A (0.61) | RAB9ANPC1KDM4EHTTATM | |
| SCHEMBL24666065 | 0.83 | METAP1 (0.46) | RAB9ANPC1KDM4EHTTATM | |
| SCHEMBL550667 | 0.83 | METAP1 (0.46) | RAB9ANPC1KDM4ESMN1; SMN2NPSR1 | |
| SCHEMBL29476654 | 0.83 | METAP1 (0.46) | RAB9ANPC1HTTSMN1; SMN2KMT2A | |
| SCHEMBL18803797 | 0.83 | METAP1 (0.46) | RAB9ANPC1POLBMETAP1 | |
| SCHEMBL5467365 | 0.83 | RAB9A (0.50) | RAB9ANPC1SMN1; SMN2NPSR1KMT2A | |
| SCHEMBL30511949 | 0.83 | RAB9A (0.50) | RAB9ANPC1SMN1; SMN2NPSR1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 166 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111763206-A | Method for efficiently preparing azaindole CRTH2 receptor antagonist intermediate | 北京桦冠医药科技有限公司 | 2020-10-13 | — | — | CN | claimed |
| CN-111349095-A | Method for preparing azaindole compound | 北京桦冠医药科技有限公司 | 2020-06-30 | — | — | CN | claimed |
| CN-106279156-A | A kind of synthetic method of 5 chlorine 7 azaindoles | 叶芳 | 2017-01-04 | — | — | CN | claimed |
| CN-105777748-A | 7-azaindole and preparation method thereof | 叶芳 | 2016-07-20 | — | — | CN | claimed |
| CN-105646485-A | Synthesizing method of 7-azaindole | 苏州艾缇克药物化学有限公司 | 2016-06-08 | — | — | CN | claimed |
| US-20250304576-A1 | IKK INHIBITORS | CANCER RESEARCH TECH LTD (GB) | 2025-10-02 | — | — | US | disclosed |
| EP-4522597-A1 | IKK INHIBITORS | Cancer Research Technology Limited (GB) | 2025-03-19 | — | — | EP | disclosed |
| US-12076411-B2 | Anti-HER2 antibody-maytansine conjugates and methods of use thereof | REDWOOD BIOSCIENCE, INC. (US) | 2024-09-03 | — | — | US | disclosed |
| WO-2023218201-A1 | IKK INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-11-16 | — | — | WO | disclosed |
| US-20230056447-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-02-23 | — | — | US | disclosed |
| EP-3807251-B1 | PHENYL AND PYRIDINYL SUBSTITUTED IMIDAZOLES AS MODULATORS OF RORYT | JANSSEN PHARMACEUTICA NV (BE) | 2022-09-07 | — | — | EP | disclosed |
| US-11345666-B2 | Phenyl and pyridinyl substituted imidazoles as modulators of RORγT | JANSSEN PHARMACEUTICA NV (BE) | 2022-05-31 | — | — | US | disclosed |
| US-5681959-A | DEPROTONATION OF A 2-AMINO-3-ALKYLPYRIDINE WITH AN ALKYLLITHIUM COMPOUND, THEN REACTION WITH AN AMIDE OR ESTER AND TREATMENT WITH A CONCENTRATED ACID FOR CYCLIZATION | MERCK, SHARP & DOHME LTD. (GB) | 1997-10-28 | — | — | US | disclosed |
| EP-0640080-A1 | SUBSTITUTED INDOLES AND AZAINDOLES AS ANGIOTENSIN II ANTAGONISTS. | SYNTEX INC (US) | 1995-03-01 | — | — | EP | disclosed |
| US-5380739-A | Angiotensin II antagonists | SYNTEX (U.S.A.) INC. (US) | 1995-01-10 | — | — | US | disclosed |
| EP-0625970-A1 | SULFONAMIDE HERBICIDES. | AGREVO UK LTD (GB) | 1994-11-30 | — | — | EP | disclosed |
| WO-1993023391-A1 | SUBSTITUTED INDOLES AND AZAINDOLES AS ANGIOTENSIN II ANTAGONISTS | SYNTEX (U.S.A.) INC. (US) | 1993-11-25 | — | — | WO | disclosed |
| CN-1078469-A | Substituted indole, the assorted indoles of ammonia and tetrahydro-1 H-pyrrolo be [2,3-c] pyridin-7-one derivatives also | SYTEX A INC (US) | 1993-11-17 | — | — | CN | disclosed |
| US-5212195-A | Substituted indole antagonists derivatives which are angiotensin II | SYNTEX (U.S.A.) INC. (US) | 1993-05-18 | — | — | US | disclosed |
| WO-1993009099-A2 | SULFONAMIDE HERBICIDES | AGREVO UK LIMITED (GB) | 1993-05-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304576-A1 | IKK INHIBITORS | NFKBIA, IKBKE, IKBKB | RAB9A 2770/4885NPC1 1965/4885KDM4E 1442/4885 |
| US-12076411-B2 | Anti-HER2 antibody-maytansine conjugates and methods of use thereof | ERBB2, EGFR, ERBB3 | RAB9A 1226/4885NPC1 3345/4885KDM4E 2372/4885 |
| US-11345666-B2 | Phenyl and pyridinyl substituted imidazoles as modulators of RORγT | RORC, RORB, RORA | RAB9A 1475/4885NPC1 3538/4885KDM4E 919/4885 |
| US-20230056447-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | RAB9A 3462/4885NPC1 4595/4885KDM4E 391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.